Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
28
UTMD Quote, Financials, Valuation and Earnings
Last price:
$63.49
Seasonality move
:
-0.41%
Day range:
$62.86 - $64.24
52-week range:
$51.26 - $65.00
Dividend yield:
1.91%
P/E ratio:
18.45x
P/S ratio:
5.40x
P/B ratio:
1.72x
Volume:
7.9K
Avg. volume:
13.1K
1-year change:
5.18%
Market cap:
$204.6M
Revenue:
$38.5M
EPS (TTM):
$3.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
-- | -- | -- | -- | -- |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
WINT
Windtree Therapeutics, Inc.
|
-- | -$39.00 | -- | -94.17% | $4.0000 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
$64.20 | -- | $204.6M | 18.45x | $0.31 | 1.91% | 5.40x |
|
AGEN
Agenus, Inc.
|
$2.85 | $12.33 | $103M | -- | $0.00 | 0% | 0.72x |
|
CRIS
Curis, Inc.
|
$1.08 | $14.00 | $14M | -- | $0.00 | 0% | 1.03x |
|
LADX
LadRx Corp.
|
$0.10 | -- | $51.2K | 0.84x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.27 | $5.50 | $37.3M | -- | $0.00 | 0% | 4.35x |
|
WINT
Windtree Therapeutics, Inc.
|
$0.0091 | $4.0000 | $306.8K | 0.00x | $0.00 | 0% | 0.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
-- | 1.050 | -- | 34.36x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
|
WINT
Windtree Therapeutics, Inc.
|
974.23% | 2.926 | 568.87% | 0.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
$4.7M | $2.4M | 9.55% | 9.57% | 27% | $3.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
WINT
Windtree Therapeutics, Inc.
|
-$360K | -$3.8M | -320.18% | -760.4% | -- | -$6.4M |
Utah Medical Products, Inc. vs. Competitors
-
Which has Higher Returns UTMD or AGEN?
Agenus, Inc. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of -116.82%. Utah Medical Products, Inc.'s return on equity of 9.57% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.52.31% $0.80 $119.3M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About UTMD or AGEN?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 332.75%. Given that Agenus, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Agenus, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 AGENAgenus, Inc.2 1 0 -
Is UTMD or AGEN More Risky?
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock UTMD or AGEN?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or AGEN?
Utah Medical Products, Inc. quarterly revenues are $9M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Utah Medical Products, Inc.'s net income of $2.6M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus 0.72x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.5.40x 18.45x $9M $2.6M AGENAgenus, Inc.0.72x -- $30.2M $63.9M
-
Which has Higher Returns UTMD or CRIS?
Curis, Inc. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of -243.36%. Utah Medical Products, Inc.'s return on equity of 9.57% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.52.31% $0.80 $119.3M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About UTMD or CRIS?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1196.3%. Given that Curis, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Curis, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 CRISCuris, Inc.4 0 0 -
Is UTMD or CRIS More Risky?
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock UTMD or CRIS?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or CRIS?
Utah Medical Products, Inc. quarterly revenues are $9M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Curis, Inc.'s net income of -$7.7M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus 1.03x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.5.40x 18.45x $9M $2.6M CRISCuris, Inc.1.03x -- $3.2M -$7.7M
-
Which has Higher Returns UTMD or LADX?
LadRx Corp. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of --. Utah Medical Products, Inc.'s return on equity of 9.57% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.52.31% $0.80 $119.3M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About UTMD or LADX?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 434682.61%. Given that LadRx Corp. has higher upside potential than Utah Medical Products, Inc., analysts believe LadRx Corp. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 LADXLadRx Corp.0 0 0 -
Is UTMD or LADX More Risky?
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
-
Which is a Better Dividend Stock UTMD or LADX?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or LADX?
Utah Medical Products, Inc. quarterly revenues are $9M, which are larger than LadRx Corp. quarterly revenues of --. Utah Medical Products, Inc.'s net income of $2.6M is higher than LadRx Corp.'s net income of -$719.3K. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.5.40x 18.45x $9M $2.6M LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns UTMD or PSTV?
Plus Therapeutics, Inc. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of -316.61%. Utah Medical Products, Inc.'s return on equity of 9.57% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.52.31% $0.80 $119.3M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About UTMD or PSTV?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1928.02%. Given that Plus Therapeutics, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is UTMD or PSTV More Risky?
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock UTMD or PSTV?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or PSTV?
Utah Medical Products, Inc. quarterly revenues are $9M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus 4.35x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.5.40x 18.45x $9M $2.6M PSTVPlus Therapeutics, Inc.4.35x -- $1.4M -$4.4M
-
Which has Higher Returns UTMD or WINT?
Windtree Therapeutics, Inc. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of --. Utah Medical Products, Inc.'s return on equity of 9.57% beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.52.31% $0.80 $119.3M WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M -
What do Analysts Say About UTMD or WINT?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 43856.04%. Given that Windtree Therapeutics, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 WINTWindtree Therapeutics, Inc.0 0 0 -
Is UTMD or WINT More Risky?
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.733%.
-
Which is a Better Dividend Stock UTMD or WINT?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or WINT?
Utah Medical Products, Inc. quarterly revenues are $9M, which are larger than Windtree Therapeutics, Inc. quarterly revenues of --. Utah Medical Products, Inc.'s net income of $2.6M is higher than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.5.40x 18.45x $9M $2.6M WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Sell
21
ICLR alert for Feb 13
ICON plc [ICLR] is down 39.93% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 36.39% over the past day.
Buy
71
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 35.78% over the past day.
